Elicio Therapeutics, Inc. (ELTX)

Elicio Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	17.62	12.89	6.16	9.28	14.97
Cash & Short-Term Investments	17.62	12.89	6.16	9.28	14.97
Cash Growth	36.64%	109.45%	-33.66%	-38.01%	119.78%
Prepaid Expenses	-	2.43	2.27	0.18	0.17
Restricted Cash	-	0.72	1.64	0.15	0.15
Other Current Assets	3.08	0.3	0.65	0.76	0.17
Total Current Assets	20.69	16.35	10.72	10.36	15.45
Property, Plant & Equipment	-	7.28	8.5	0.89	1.02
Other Long-Term Assets	7.49	3.52	3.45	3.57	3.18
Total Assets	28.18	27.15	22.66	14.81	19.66
Accounts Payable	-	4.37	2.81	1.68	1.65
Accrued Expenses	-	3.76	1.94	2.32	1.22
Short-Term Debt	-	-	-	11.8	-
Current Portion of Leases	-	0.91	0.69	-	0.44
Other Current Liabilities	11.52	0.73	1.44	3.09	-
Total Current Liabilities	11.52	9.77	6.87	18.88	3.31
Long-Term Leases	-	6.01	6.79	-	-
Other Long-Term Liabilities	27.97	-	0.09	0.03	-
Total Liabilities	39.49	15.77	13.75	18.91	3.31
Common Stock	-11.31	0.1	0	0.17	0.13
Additional Paid-In Capital	-	153.83	4.86	4.09	3.34
Retained Earnings	-	-142.2	-107.01	-78.8	-52.4
Treasury Stock	-	-0.15	-	-	-
Comprehensive Income & Other	-	-0.2	-	-	-0.21
Total Common Equity	-11.31	11.37	-102.15	-74.54	-49.14
Shareholders' Equity	-11.31	11.37	8.92	-4.1	16.35
Total Liabilities & Equity	28.18	27.15	22.66	14.81	19.66
Total Debt	-	6.92	7.48	11.8	0.44
Net Cash (Debt)	17.62	5.98	-1.33	-2.52	14.53
Net Cash Growth	194.76%	-	-	-	144.47%
Net Cash Per Share	1.44	1.18	-4.19	-0.16	1.35
Filing Date Shares Outstanding	13.65	10.22	17.7	17.14	13.06
Total Common Shares Outstanding	13.65	9.6	17.7	17.14	13.06
Working Capital	9.17	6.58	3.85	-8.52	12.15
Book Value Per Share	-0.83	1.18	-5.77	-4.35	-3.76
Tangible Book Value	-11.31	11.37	-102.15	-74.54	-49.14
Tangible Book Value Per Share	-0.83	1.18	-5.77	-4.35	-3.76
Machinery	-	1.82	2.15	-	1.12
Leasehold Improvements	-	0.13	0.12	-	-

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q